8-K
Anavex Life Sciences Corp. (AVXL)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) oftheSecurities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 27, 2021
ANAVEX LIFE SCIENCES CORP.
(Exact name of registrant as specified in its charter)
| Nevada | 001-37606 | 98-0608404 |
|---|---|---|
| (State or other jurisdiction | (Commission | (IRS Employer |
| of incorporation) | File Number) | Identification No.) |
| 51 West 52nd Street **** <br><br>7th Floor **** <br><br>New York, NY USA 10019 <br><br>(Address of principal executive offices) (Zip Code) | ||
| --- |
1-844-689-3939
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications<br>pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material<br>pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications<br>pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications<br>pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Titleof Each Class | TradingSymbol | Nameof Each Exchange on Which Registered |
|---|---|---|
| Common<br>Stock, par value $0.001 per share | AVXL | The<br>Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 8.01 | OtherEvents. |
|---|
On September 21, 2021, Anavex Life Sciences Corp., a Nevada corporation (the “Company”) received an approval letter from The Nasdaq Stock Market LLC approving the Company’s application to list the Company’s common stock, par value $0.001 per share (the “Common Stock”), on the Nasdaq Global Select Market. Shares of the Company’s Common Stock were previously listed on the Nasdaq Capital Market. The Company’s Common Stock is expected to begin trading on the Nasdaq Global Select Market under its current ticker symbol, “AXVL”, as of market open September 27, 2021.
On September 27, 2021, the Company issued a press release (the “Press Release”) announcing the commencement of trading of its Common Stock on the Nasdaq Global Select Market. A copy of the Press Release is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. | |
|---|---|---|
| (d) | Exhibits | |
| --- | --- | |
| EXHIBITNO. | DESCRIPTION | LOCATION |
| --- | --- | --- |
| 99.1 | Press Release | Furnished herewith |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ANAVEX LIFE SCIENCES CORP. | |
|---|---|
| By: | /s/Christopher Missling |
| Name:<br>Christopher Missling, PhD<br> Title: Chief Executive Officer |
Date: September 27, 2021
Exhibit 99.1
Anavex Life Sciences Announces Uplistingto the NASDAQ Global Select Market®
NEW YORK – September 27, 2021 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that effective as of market open today, September 27, 2021, its shares of common stock have been approved for uplisting to the NASDAQ Global Select Market® and will continue trading under its current ticker symbol AVXL.
“We are honored to be added to the NASDAQ Global Select Market®, joining some of the most respected companies in the world who also uphold NASDAQ’s rigorous qualification standards,” said Christopher U Missling, PhD, President & Chief Executive Officer of Anavex. “Inclusion in this listing further emphasizes our overall growth as a company, as well as our long-term growth potential.”
Anavex was previously listed on the NASDAQ Capital Market. Anavex’s shares will be transferred to the Global Select Market at the opening of business today, September 27, 2021, and will continue to be traded under the ticker AVXL.
The Nasdaq Global Select Market® is a mark of achievement and stature for qualified companies. Listed companies must meet financial and liquidity requirements and satisfy corporate governance and disclosure requirements on both an initial and continuing basis.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex’s lead drug candidate, ANAVEX®2-73 (blarcamesine), successfully completed a Phase 2a clinical trial for Alzheimer’s disease and recently a Phase 2 proof-of-concept study in Parkinson’s disease dementia and a Phase 2 study in adult patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson’s Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson’s disease. ANAVEX®3-71, which targets sigma-1 and muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the company on Twitter, Facebook, Instagram and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com
Investors:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: andrew@barwicki.com